Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
Open Access
- 5 July 2013
- journal article
- review article
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 32 (7) , 376-379
Abstract
Deregulation of the phosphatidylinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis. Thus, small molecules targeting this pathway are under active development as anticancer therapeutics. Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising clinical efficacy against human cancers, the emergence of drug resistance may limit their success in the clinic. To date, several resistance mechanisms, including both PI3K-dependent and -independent mechanisms, have been described. Here, we summarize the current understanding of resistance mechanisms to PI3K-mTOR inhibitors and discuss potential strategies for overcoming resistance for potential clinical application.Keywords
This publication has 33 references indexed in Scilit:
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPsScience, 2010
- Targeting the PI3K signaling pathway in cancerCurrent Opinion in Genetics & Development, 2010
- The Pharmacology of mTOR InhibitionScience Signaling, 2009
- Defining the Role of mTOR in CancerCancer Cell, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKBMolecular Cell, 2006
- Upstream and downstream of mTORGenes & Development, 2004
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997